Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Liver

• Publication date

  2008-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1600-0676.1993.TB00644.XPMID 7505044
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in swedish blood donors

  1993cited by this paper
• Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

  1992cited by this paper
• HCV RNA in serum of asymptomatic blood donors involved in post-transfusion hepatitis (PTH).

  1991cited by this paper
• Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis.

  1991cited by this paper
• Hepatitis C viral RNA in serum of patients with chronic non‐A, non‐B hepatitis: Detection by the polymerase chain reaction using multiple primer sets

  1991cited by this paper
• Long-term persistence of hepatitis C virus antibodies in a single source outbreak.

  1991cited by this paper
• Sequence variation in hepatitis C viral isolates.

  1991cited by this paper
• Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates.

  1990cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Acute viral hepatitis, types A, B and non-A, non-B: a prospective study of the epidemiological, laboratory and prognostic aspects in 280 consecutive cases.

  1981cited by this paper

• Prevalence of Thyroid Dysfunction in Patients with Hepatitis C Virus Infection: A Cross-sectional Study

  2025cites this paper
• Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot

  2023cites this paper
• PREVALENCE OF LIPID PEROXIDATION AND HEPATIC PROFILE IN HEPATITIS C PATIENTS RECEIVING SOFOSBUVIR AND RIBAVIRIN FROM LAHORE-PAKISTAN Hepatic Profile In Hepatitis C Patients

  2020cites this paper
• Chapter 1 Epidemiology and Prevention of Viral Hepatitis B and C

  2018cites this paper
• Peromyscus as a model system for human hepatitis C: An opportunity to advance our understanding of a complex host parasite system.

  2017cites this paper
• Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis

  2016cites this paper
• Natural history of chronic hepatitis C

  2016cites this paper
• From THE DEPARTMENT OF MEDICINE, SOLNA Karolinska Institutet, Stockholm, Sweden CHRONIC HEPATITIS MORBIDITY AND MORTALITY IN PATIENTS AND THEIR CHILDREN

  2016cites this paper
• New biomarkers for clinical management of hepatitis C virus infected patients

  2015cites this paper
• Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study

  2015cites this paper
• Hepatitis C risk factors in a Cambodian American population in Lowell, Massachusetts

  2015cites this paper
• Liver fibrosis progression in hepatitis C virus infection after seroconversion.

  2015cites this paper
• Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.

  2014cites this paper
• Epidemiology and Prevention of Viral Hepatitis B and C

  2013cites this paper
• Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response

  2012cites this paper
• NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferon–Ribavirin Therapy in Egyptian Patients

  2012cites this paper
• Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated‐interferon/ribavirin combination therapy

  2011cites this paper
• Immunopathogenesis of HIV/hepatitis C virus coinfection

  2011cites this paper
• EFFICACYAND SAFETY OF INTERFERON ALPHA 2 B PLUS RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C PATIENTS WITH PULMONARY TUBERCULOSIS

  2011cites this paper
• On the outcome of antiviral therapy for hepatitis C virus genotype 2 or 3 infection

  2011cites this paper
• Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

  2010cites this paper
• Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection

  2010cites this paper
• Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C

  2009cites this paper
• The history of the “natural history” of hepatitis C (1968–2009)

  2009cites this paper
• Prognosis of hepatitis C virus‐infected Canadian post‐transfusion compensation claimant cohort

  2009cites this paper
• Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.

  2009cites this paper
• Sroczynski G. et al. (2010) Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. Journal of Viral Hepatitis, 17(1):34-50

  2009cites this paper
• Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil.

  2009cites this paper
• Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.

  2008cites this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cites this paper
• Article Commentary: Occupational Risks of Blood Exposure in the Operating Room

  2007cites this paper
• Supporting Informed Decisions Pegylated Interferon Combined with Ribavirin for Chronic Hepatitis C Virus Infection: An Economic Evaluation

  2007cites this paper
• Modelling outcomes of HCV in recipients of blood products.

  2007cites this paper
• National Centre in HIV Epidemiology and Clinical Research

  2006cites this paper
• Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and Along Gender

  2006cites this paper
• Patients' experiences related to anti-viral treatment for hepatitis C.

  2006cites this paper
• Acute hepatitis C infection in HIV co-infection : epidemiology, natural history and the host-viral responses

  2006cites this paper
• Antivirale Kombinationstherapie bei Patienten mit chronischer Hepatitis C in Österreich. Gesundheitsökonomische Evaluation der Kombinationstherapie mit Interferon/Peginterferon und Ribavirin

  2006cites this paper
• Natural history and management of hepatitis C in East London

  2006cites this paper
• Efforts to define the natural history of chronic hepatitis C continue.

  2006cites this paper
• Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment.

  2005cites this paper
• Challenges and Controversies in the Management of Hepatitis C Virus Infection (Part 1)

  2005cites this paper
• Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany

  2005cites this paper
• Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.

  2005cites this paper
• Natural history of hepatitis C.

  2005cites this paper
• Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security

  2005cites this paper
• Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.

  2005cites this paper
• Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study.

  2005cites this paper
• Viral hepatitis and hepatocellular carcinoma

  2005cites this paper
• Expression of Hepatitis C Virus Core Protein in Hepatocytes Does Not Modulate Proliferation or Apoptosis of CD8+ T Cells

  2005cites this paper
• Improving the accuracy of long‐term prognostic estimates in hepatitis C virus infection

  2004cites this paper
• Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990

  2004cites this paper
• Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus‐positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus

  2004cites this paper
• Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance

  2004cites this paper
• Natural history of initially mild chronic hepatitis C.

  2004cites this paper
• Histopathology and detection of hepatitis C virus in liver

  2004cites this paper
• Estimating the Date of Hepatitis C Virus Infection from Patient Interviews and Antibody Tests on Stored Sera

  2004cites this paper
• Hepatitis C infection: the quest for new treatment strategies

  2004cites this paper
• HEPATITIS Cost effectiveness of peginterferon α2 b plus ribavirin versus interferon α2 b plus ribavirin for initial treatment of chronic hepatitis C

  2003cites this paper
• Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

  2003cites this paper
• Hepatitis C in the General Adult Population of Oslo: Prevalence and Clinical Spectrum

  2003cites this paper
• Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

  2003cites this paper
• The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?

  2003cites this paper
• Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment

  2003cites this paper
• Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

  2003cites this paper
• Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum.

  2003cites this paper
• Natural History of Hepatitis C

  2002cites this paper
• Natural history of chronic hepatitis C

  2002cites this paper
• Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies

  2002cites this paper
• Natural history of chronic hepatitis C

  2002cites this paper
• Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.

  2002cites this paper
• Natural history of chronic hepatitis C: identifying a window of opportunity for intervention.

  2001cites this paper
• Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

  2001cites this paper
• Comparison of clinical, virologic and pathologic features in patients with acute hepatitis B and C

  2001cites this paper
• Natural history of hepatitis C infection: a concise review.

  2001cites this paper
• HCV genotypes and age distribution in patients of Vienna and surrounding areas.

  2001cites this paper
• Estimating progression to cirrhosis in chronic hepatitis C virus infection

  2001cites this paper
• Chronic hepatitis C virus infection and the pathogenesis of hepatocellular carcinoma.

  2001cites this paper
• Hepatitis B and hepatitis C co‐infection in patients with HIV

  2001cites this paper
• Clinico-epidemiology of hepatitis B viral infection in Northeastern Thailand.

  2000cites this paper
• Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.

  2000cites this paper
• [Chronic hepatitis by C virus. Part 2. Treatment].

  2000cites this paper
• Natural history of hepatitis C virus infection

  2000cites this paper
• Which patients with hepatitis C develop liver complications?

  2000cites this paper
• Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

  2000cites this paper
• Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study

  2000cites this paper
• Clinico-epidemiology of hepatitis C viral infection in northeastern Thailand.

  2000cites this paper
• Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome

  2000cites this paper
• [The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible?].

  2000cites this paper
• The prevalence of viral hepatitis (HAV, HBV and HCV) in the Christchurch community.

  2000cites this paper
• Natural history and disease manifestations of hepatitis C infection.

  2000cites this paper
• Natural History , Treatment , and Prevention of Hepatitis C Moderator :

  2000cites this paper
• The natural history of hepatitis C virus infection.

  2000cites this paper
• Why is there such difficulty in defining the natural history of hepatitis C?

  2000cites this paper
• The natural history of hepatitis C virus infection: host, viral, and environmental factors.

  2000cites this paper
• Economic analysis of recombinant interferon α 2b in the treatment of chronic hepatitis B and C

  2000cites this paper
• 12 Hepatitis C and cirrhosis

  2000cites this paper
• Hepatite crônica por virus C. Parte 2. Tratamento

  2000cites this paper
• Verlauf und Therapie der akuten Hepatitis-C-Virusinfektion. Ist eine Prävention der Chronifizierung möglich?

  2000cites this paper
• L'histoire naturelle de l'infection par le virus de l'hépatite c

  2000cites this paper